已收盘 02-06 16:00:00 美东时间
+1.084
+1.58%
Verastem Projects Cash Runway Into First Half of 2027 Verastem Inc. reported preliminary, unaudited net product revenues of approximately $17.5 million for the fourth quarter of 2025 and about $30.9 million for the full year 2025, reflecting the launch of AVMAPKI™ FAKZYNJA™ CO-PACK in May following
02-04 20:34
Verastem erwartet für 2025 einen Umsatz von rund 30,9 Millionen US-Dollar und eine Liquiditätsreichweite bis 2027 Verastem Inc. meldet für das Geschäftsjahr 2025 vorläufige, ungeprüfte Nettoproduktumsätze von rund 30,9 Millionen US-Dollar für das AVMAPKI™ FAKZYNJA™ CO-PACK, nachdem das Produkt im Ma
02-04 20:34
Verastem Inc. reports FY2025 net product revenue of USD 30.9 million Verastem Inc. reported preliminary, unaudited net product revenues of approximately USD 17.5 million for the fourth quarter (Q4) of 2025 and approximately USD 30.9 million for the full year (FY) 2025, following U.S. FDA approval of
02-04 20:31